Anixa Biosciences Secures U.S. Patent for Breast Cancer Vaccine Technology, Extending IP Protection into 2040s

Anixa Biosciences has been awarded a key U.S. patent for its breast cancer vaccine technology, extending protection into the 2040s. The vaccine targets α-lactalbumin protein, a protein found in normal breast tissue during lactation and in certain breast cancers. The patent covers novel methods of inducing an immune response to this protein, reinforcing the Company's commitment to addressing breast cancer in healthy women. The vaccine has the potential to fundamentally change how breast cancer is prevented and could benefit hundreds of thousands of women each year.